SUNAK Study: Sunphenon EGCg (Epigallocatechin Gallate) in the early stage of Alzheimer's disease
In this study, we investigated whether the regular taking of the extract of green tea (epigallocatechin gallate, EGCG) can slow the progression of the disease in patients with Alzheimer's disease. This is a multi-center, randomized, placebo-controlled, double-blind study. Participation was open to male and female patients, from the age of 60, who have been diagnosed with Alzheimer's type dementia, who were in an early phase of the disease. The study medicine was taken twice a day as a capsule.
Study Director: Prof. Dr. Friedemann Paul (WG Clinical Neuroimmunology, NCRC, ECRC)
Course of the study: 10/2009 - 2015
This study is registered in the database clinicaltrials.gov (NCT00951834).